Core Insights - The collaboration between the company and Huawei has deepened in recent years, leading to the development of comprehensive AI innovation solutions across multiple industries [2] Group 1: Partnership and Collaboration - In September, the company and Huawei jointly launched AI innovation solutions by integrating the company's industry knowledge and AI capabilities with Huawei's ICT infrastructure [2] - The partnership focuses on strategic alignment in areas such as multi-industry scenario innovation and the integration of AI large models with hardware [2] Group 2: Technological Integration - The company's "1+2+N" industrial AI-driven enterprise intelligence operation framework will utilize Huawei's Kunpeng servers and OceanStor storage for unified data connectivity, modeling, and analysis capabilities [2] - The company's self-developed time series large model TPT and hypergraph large model HGT will be trained and inferred on Huawei's Ascend AI computing platform to enable automation in production processes and enterprise operations [2] Group 3: Future Developments - The new generation of the company's Universal Control System (UCS) will be deeply integrated with Huawei's Kunpeng hardware, redefining the product form and application value of control systems through software definition and cloud-native technology [2] - The company plans to explore a new industrial service ecosystem by combining its offline PlantMate 5S store with the online PlantMart marketplace [2]

Core Viewpoint - The company Lingyun Guang announced that its wholly-owned subsidiary, Lingyun Guang Technology International Co., Ltd., plans to invest up to $5 million as a cornerstone investor in the initial public offering of Beijing Zhipu Huazhang Technology Co., Ltd. on the Hong Kong Stock Exchange, which is considered an affiliated transaction but does not constitute a major asset restructuring [1] Group 1 - The investment will utilize the company's own funds and has been approved by the company's board and independent directors, thus not requiring shareholder approval [1] - Zhipu's recent financial performance shows negative equity of -3.95514 billion yuan and -6.15084 billion yuan for the last two reporting periods, with net losses of -2.95801 billion yuan and -2.35785 billion yuan respectively [1] - This external investment aligns with the company's long-term strategic direction and is expected to strengthen the partnership and promote the development and commercialization of AI innovative solutions [1]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 AI技术的飞速发展，为生物医药企业的研发、生产、销售等各个环节注入了强大的创新动力，助力企业在 激烈的市场竞争中脱颖而出。为了帮助生物医药企业管理者更好地把握这一趋势，深入探索AI技术在生物 医药领域的应用潜力，中关村联新生物医药联盟和IBM将举办一场生物医药行业开放日，诚邀生物医药产 业、医疗卫生产业领域人员拨冗出席。 活动时间： 2025年3月27日（周四）下午13:30-17:30 地点： IBM创新体验中心（具体地址报名审核后通知） 报名人数： 30人以内（报名有审核） https://docs.qq.com/form/page/DUHhPZExnZGhSUXhJ 或扫描下方二维码进行填写 IBM创新体验中心介绍： 开放日安排 1. AI创新解决方案体验之旅IBM最新、最前沿的AI创新解决方案，沉浸式体验让您感受AI技术如何为不 同行业带来颠覆性的变革，更有医药行业相关方案为您带来AI新启发。 2. 加速AI规模应用，释放数智生产力A ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 AI技术的飞速发展，为生物医药企业的研发、生产、销售等各个环节注入了强大的创新动力，助力企业在 激烈的市场竞争中脱颖而出。为了帮助生物医药企业管理者更好地把握这一趋势，深入探索AI技术在生物 医药领域的应用潜力，中关村联新生物医药联盟和IBM将举办一场生物医药行业开放日，诚邀生物医药产 业、医疗卫生产业领域人员拨冗出席。 活动时间： 2025年3月27日（周四）下午13:30-17:30 地点： IBM创新体验中心（具体地址报名审核后通知） 报名人数： 30人以内（报名有审核） 开放日安排 1. AI创新解决方案体验之旅IBM最新、最前沿的AI创新解决方案，沉浸式体验让您感受AI技术如何为不 同行业带来颠覆性的变革，更有医药行业相关方案为您带来AI新启发。 2. 加速AI规模应用，释放数智生产力AI技术的价值不仅在于创新，更在于其能够大规模落地应用，为企 业创造实实在在的效益。在这一环节，IBM团队将分享企业如何构建自己的AI能力进行业务赋能 ...